Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial by Blay, Jean-Yves, Prof, Chevret, Sylvie, Prof, Le Cesne, Axel, Prof, Brahmi, Mehdi, MD, Penel, Nicolas, Prof, Cousin, Sophie, MD, Bertucci, Francois, Prof, Bompas, Emmanuelle, MD, Ryckewaert, Thomas, MD, Soibinet, Pauline, MD, Boudou-Rouquette, Pascaline, MD, Saada Bouzid, Esma, MD, Soulie, Patrick, MD, Valentin, Thibaud, MD, Lotz, Jean-Pierre, Prof, Tosi, Diego, MD, Neviere, Zoé, MD, Cancel, Mathilde, MD, Ray-Coquard, Isabelle, Prof, Gambotti, Laetitia, MD, Legrand, Frédéric, PhD, Lamrani-Ghaouti, Assia, PhD, Simon, Clotilde, PhD, Even, Caroline, MD, Massard, Christophe, Prof

Get full text

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-lab... by Vano, Yann-Alexandre, MD, Elaidi, Réza, PhD, Bennamoun, Mostefa, MD, Chevreau, Christine, Prof, Borchiellini, Delphine, MD, Pannier, Diane, MD, Maillet, Denis, MD, Gross-Goupil, Marine, MD, Tournigand, Christophe, Prof, Laguerre, Brigitte, MD, Barthélémy, Philippe, MD, Coquan, Elodie, MD, Gravis, Gwenaëlle, Prof, Houede, Nadine, Prof, Cancel, Mathilde, MD, Huillard, Olivier, MD, Beuzeboc, Philippe, MD, Fournier, Laure, Prof, Méjean, Arnaud, Prof, Cathelineau, Xavier, Prof, Doumerc, Nicolas, MD, Paparel, Philippe, Prof, Bernhard, Jean-Christophe, Prof, de la Taille, Alexandre, Prof, Bensalah, Karim, Prof, Tricard, Thibault, MD, Waeckel, Thibaut, MD, Pignot, Géraldine, MD, Braychenko, Elena, MD, Caruso, Stefano, PhD, Sun, Cheng-Ming, PhD, Verkarre, Virginie, MD, Lacroix, Guillaume, MSc, Moreira, Marco, Meylan, Maxime, PhD, Bougouïn, Antoine, Phan, Letuan, MSc, Thibault-Carpentier, Christelle, PhD, Zucman-Rossi, Jessica, Prof, Fridman, Wolf Herman, Prof, Sautès-Fridman, Catherine, Prof, Oudard, Stéphane, Prof

Get full text